Published on:
You have probably heard of a PSA test for prostate cancer, and you may also have come across terms like "genetic cancer predisposition testing" or "hereditary cancer panels." Both relate to cancer, yet they do very different things. A PSA test and other tumour markers measure substances in your body that may indicate the presence of cancer right now. A genetic cancer predisposition test reads your DNA to determine whether you inherited mutations that raise your lifetime risk of developing cancer in the future.
Understanding this distinction matters because each type of test leads to different clinical decisions, different follow-up pathways, and different conversations with your doctor. Confusing one with the other can leave you either falsely reassured or unnecessarily anxious.
When your GP requests a PSA (prostate-specific antigen) test, the laboratory measures a protein that your prostate gland produces. Higher concentrations of this protein in your blood can point towards prostate cancer, but they can also rise because of benign prostatic hyperplasia, prostatitis, or even recent vigorous exercise. PSA is one example of a broader group known as cancer biomarkers, or tumour markers.
Tumour markers are measurable substances that cancerous cells, or normal cells responding to malignancy, release into the blood, urine, or tissue. Other commonly used markers include CA-125 (monitored in ovarian cancer), CEA (associated with colorectal and other cancers), and AFP (linked to liver cancer and certain testicular tumours). Each marker reflects a specific protein or molecule tied to a particular cancer type.
What all tumour markers share is a focus on the present. They capture a biochemical snapshot of your body at the moment the sample is taken. A rising PSA across successive tests might prompt your doctor to recommend a prostate screening investigation, including imaging or biopsy. But the PSA figure alone does not explain why it has risen, and it reveals nothing about whether you inherited a heightened vulnerability to prostate cancer.
PSA screening has been available since the late 1980s, and large-scale studies, such as the European Randomised Study of Screening for Prostate Cancer (ERSPC), suggest it can help reduce prostate cancer mortality in screened populations, though the overall benefits must be weighed against the harms of overdiagnosis and overtreatment. The test has well-documented limitations. A PSA level above 4 ng/mL is traditionally flagged as elevated, but roughly 15% of men with readings below that threshold may still harbour prostate cancer. Simultaneously, many men with elevated PSA levels have no malignancy at all.
This imprecision creates two problems. False-positive results may lead to unnecessary biopsies, an invasive procedure carrying risks of infection, bleeding, and anxiety. False-negative results can provide unwarranted reassurance. In the United States, the US Preventive Services Task Force advises men aged 55 to 69 to discuss the decision to undergo PSA screening with their doctor based on individual circumstances, rather than recommending routine screening for all. In the UK, there is no national PSA screening programme. However, through the NHS Prostate Cancer Risk Management Programme, men aged 50 and over can request a PSA test after an informed discussion with their GP about the potential benefits and limitations of testing.
Researchers have developed newer biomarker combinations to sharpen accuracy. The Prostate Health Index (phi) merges three PSA isoforms into a single score that may better separate cancer from benign conditions. Urine-based tests such as PCA3 measure gene expression patterns specific to prostate cancer tissue. The Mi-Prostate Score (MiPS) combines PCA3 with the TMPRSS2-ERG gene fusion marker and serum PSA, potentially boosting both sensitivity and specificity beyond what any single marker achieves. A 2016 review in Cellular Oncology concluded that a panel of markers, rather than a single test, is more suitable for prostate cancer diagnosis given the disease's heterogeneity.
These refined panels represent progress, but they remain detection tools. They describe current conditions in your body. They do not reveal inherited genetic risk factors that may have been present since birth.
A genetic cancer predisposition test analyses your DNA, typically from a blood or saliva sample, to identify inherited mutations that increase your lifetime risk of developing certain cancers. Unlike biomarkers that fluctuate with disease activity, inflammation, and treatment, your germline DNA stays constant from birth. A result from this type of test remains valid for your entire life.
The best-known examples are BRCA1 and BRCA2 mutations, which raise the risk of breast and ovarian cancer substantially. What many people overlook is that men who carry BRCA2 mutations face elevated prostate cancer risk too, and the cancers that develop tend to be more aggressive. Tests like ProstateNext examine 14 genes associated with hereditary prostate cancer. Broader panels, such as the Myriad MyRisk Hereditary Cancer test, screen for mutations linked to eight different hereditary cancers in a single analysis.
Genetic predisposition testing does not diagnose cancer. If your result reveals a BRCA2 mutation, that finding does not mean you have prostate cancer today. It means your risk is higher than average, and your medical team should adjust your screening schedule accordingly: starting PSA monitoring earlier, using lower thresholds to trigger further investigation, or incorporating MRI imaging sooner than standard guidelines recommend. Our cancer genetic testing page explains how these assessments are structured in clinical practice.
Though both categories relate to cancer, they answer different questions, use different methodologies, and inform different clinical decisions.
Tumour markers like PSA, CA-125, and CEA measure proteins or other molecules circulating in your blood or present in your urine and tissue. These substances reflect current biological activity: the presence and sometimes the volume of a tumour. Genetic predisposition tests examine the sequence of your DNA at specific gene locations. They search for variants (mutations) inherited from one or both parents that compromise the body's normal cancer-suppression mechanisms.
Doctors order biomarker tests for screening, diagnosis, or monitoring treatment response. A falling PSA after prostate cancer treatment suggests the therapy is working. A rising CA-125 during ovarian cancer surveillance may signal recurrence. These results change over time because the underlying biology changes.
Genetic predisposition tests need to be performed only once. The result informs risk stratification: how frequently you should be screened, at what age screening should begin, and whether preventive interventions such as enhanced surveillance or risk-reducing surgery deserve consideration. A positive result also carries implications for your blood relatives, who may share the same mutation.
PSA and similar markers are prone to false positives and false negatives because many non-cancerous conditions influence the same proteins. An elevated PSA does not confirm cancer; a normal PSA does not exclude it. Genetic predisposition tests are highly accurate at detecting the specific mutations they target. Carrying a mutation, though, does not guarantee you will develop cancer, and a negative result does not eliminate risk from non-hereditary causes. Both types of test require expert interpretation within your full clinical picture.
PSA and other tumour markers may be appropriate for periodic screening, particularly if you fall within an at-risk age group or present with symptoms that warrant investigation. Your GP might discuss PSA testing if you are a man over 50, or over 45 with a family history of prostate cancer or of Black African or Black Caribbean descent. CA-125 might be requested if a woman experiences persistent bloating, pelvic pain, or other symptoms consistent with ovarian pathology.
These tests also prove valuable for monitoring. If you have been diagnosed with cancer and are undergoing treatment, serial biomarker measurements help your oncologist gauge whether therapy is reducing tumour burden. Post-treatment surveillance follows the same logic: a rising marker can flag recurrence before symptoms appear.
Genetic testing for cancer predisposition offers the most clinical value when your personal or family history suggests a hereditary pattern. Red flags include multiple close relatives diagnosed with the same or related cancers, cancers diagnosed at unusually young ages, bilateral cancers affecting both sides of a paired organ, and rare cancer types linked to known genetic syndromes.
A genetic counselling appointment before testing helps you understand what the results might mean for you and your family, the psychological impact of a positive finding, and the practical steps that follow. A genetic counsellor will build a detailed family history, assess whether testing is appropriate for your situation, and, if you proceed, interpret the results in context.
These two categories are not competitors. They serve different roles in a comprehensive cancer risk strategy, and combining them can produce better outcomes than either approach alone.
Consider a man who undergoes genetic testing and discovers he carries a BRCA2 mutation. His doctor may recommend beginning PSA screening at age 40 rather than 50, using a lower PSA threshold to trigger further evaluation. This adjusted screening protocol, shaped by genetic risk data, may catch cancers earlier and in more treatable stages. A National Cancer Institute review notes that germline genetic variants are attractive prognostic markers because they are present, detectable, and stable throughout life, offering a reliable foundation for building a dynamic screening programme.
By contrast, a man with no concerning family history might follow standard screening guidelines: periodic PSA testing from age 50, with results interpreted alongside newer biomarker panels like phi or MiPS if the initial reading falls into an ambiguous range. For this individual, genetic predisposition testing may not add enough clinical value to justify the cost and psychological weight of the process.
Multi-marker strategies are gaining traction across oncology. Panels that combine traditional biomarkers with genomic data, imaging findings, and clinical risk factors offer a more layered assessment than any single test. The trajectory points towards personalised screening protocols tailored to each patient's genetic profile, biomarker trends, and clinical history.
No. PSA measures a protein produced by your prostate gland and reflects current prostate activity. It can be elevated by cancer, infection, enlargement, or recent physical activity. It provides no information about inherited gene mutations. You would need a separate genetic predisposition test, typically analysing a blood or saliva sample for specific gene variants, to assess hereditary risk.
Family history is the strongest indicator that genetic testing may be worthwhile, but its absence does not guarantee you carry no mutations. Some mutations arise spontaneously (de novo), and small families or incomplete medical records can obscure a hereditary pattern. A genetic counsellor can review your background and help you decide whether testing would provide useful information for your situation.
Yes. Because your germline DNA does not change over your lifetime, the result is valid indefinitely. You will not need to repeat the test. As scientific understanding advances, though, your results may be reinterpreted. A variant classified as having "uncertain significance" today could be reclassified as benign or pathogenic in future as researchers accumulate more data.
Women do not have a prostate gland and therefore do not undergo PSA testing. But the same principle applies to female-relevant biomarkers like CA-125 for ovarian cancer and to genetic predisposition tests for BRCA1 and BRCA2 mutations. Understanding the distinction between detection-focused biomarkers and risk-focused genetic tests helps women make informed decisions about their own screening and prevention strategies.
Start by discussing your personal risk factors, family history, age, and ethnicity with your GP or a specialist. If you fall within standard screening age ranges and have no unusual family history, periodic biomarker screening such as PSA testing may be the appropriate first step. If your family history raises concern about hereditary cancer, ask for a referral to a genetic counsellor who can guide you through predisposition testing and its implications.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. It is not intended to replace a consultation with a qualified healthcare professional. Always speak to your GP or specialist for personalised guidance regarding cancer screening, genetic testing, or any health concerns. If you are experiencing symptoms that worry you, please seek prompt medical attention.
The information provided in this article is for educational purposes only and is based on NHS recommendations. It is not a substitute for professional medical advice. Always consult your doctor or a qualified healthcare provider for advice on medical conditions or treatments.
Our medical centre is at 36 Spital Square, E1 6DY, City of London.
